PSR SUPPLIER REPORT
Independent review of supplier documentation, analytical testing evidence, lot traceability, pricing visibility, and company transparency.
REPORT STATUS
Initial Review
LAST REVIEWED
September 2026
SUPPLIER TYPE
Research-use supplier
LOCATION LISTED
Lithuania, European Union
AFFILIATE DISCLOSURE
PSR may receive compensation from certain supplier referral links. Affiliate relationships do not determine PSR scores, methodology, findings, or editorial conclusions.
Visit Baltic Peptides Website →
PSR Reader Offer — 10% off with code peptidesupplyreport10
AT A GLANCE
Overall Score: 89 / 100 • Strongest category: Lot Traceability (94 / 100)
Public COA access: Public COA archive • Location: Lithuania, European Union • Last reviewed: September 2026
Documented limitation: Conflicting 98% versus 99% purity-release language requires clarification.
PSR Reader Offer — 10% off with code peptidesupplyreport10
Visit Supplier Website →
PRELIMINARY PSR ASSESSMENT
89 / 100 · STRONG TRANSPARENCY
WEIGHTED OVERALL PSR TRANSPARENCY SCORE
89 / 100
Preliminary assessment pending continued documentation review. Scores reflect transparency evidence and are not a certification, guarantee, safety determination, or human-use recommendation.
DOCUMENTATION QUALITY · 25%
91 / 100
TESTING EVIDENCE · 25%
88 / 100
LOT TRACEABILITY · 20%
94 / 100
PRICING TRANSPARENCY · 15%
94 / 100
SUPPLIER TRANSPARENCY · 15%
75 / 100
EXECUTIVE SUMMARY
A neutral reading of the public record.
Baltic Peptides maintains a strong public documentation framework built around batch-specific Certificates of Analysis, third-party laboratory testing, public pricing, Lithuania-based fulfillment information, and product-level traceability. The supplier states that every production batch receives independent external testing and that COAs are published publicly before or during the period that a batch is sold.
The strongest transparency signals are Baltic’s public COA archive, batch-number organization, direct lot-to-order traceability claims, public pricing, and disclosure that testing is performed externally rather than in-house. Baltic also identifies Janoshik as a laboratory used for HPLC-UV or LC-MS analysis on its current COA page.
PSR also identified several documentation-consistency issues. Baltic’s FAQ states that released compounds meet a minimum purity threshold of ≥99%, while the COA process page contains a step describing rejection below 98%. Current shipping pages also describe thermal protection as standard on every order, while the homepage still references optional upgraded cold-chain packaging. These discrepancies are treated as documentation-consistency issues requiring clarification rather than evidence of product quality.
PSR’s assessment reflects documentation transparency and evidence availability. It is not a certification or determination of product safety, efficacy, regulatory status, or suitability for human use.
01 / DOCUMENTATION REVIEW
Documentation Quality
POSITIVE EVIDENCE
• Public COA archive
• Batch-specific certificates
• Unique lot codes
• COAs viewable without an account
• Independent external laboratory testing stated
• Janoshik specifically identified on current COA page
• HPLC-UV / LC-MS methods publicly described
• Public product pricing
• Public stock status
• Lithuania fulfillment location disclosed
• Public shipping and support information
• Order-to-batch traceability described
OPEN QUESTIONS
• Whether the operative minimum release threshold is 98% or 99%
• Whether thermal protection is always included or can be an optional paid upgrade
• Whether every active lot has an externally verifiable laboratory report ID
• Whether every batch receives identical analytical testing beyond HPLC purity
• Long-term historical COA availability after inventory changes
• Public legal-entity name and registration details
• Exact relationship between Baltic Peptides, Baltic BioLabs, and upstream production partners
PSR OBSERVATION
Baltic Peptides demonstrates strong documentation accessibility and lot-level transparency, particularly through its public COA archive and batch-specific testing structure. However, PSR identified conflicting language across current supplier pages regarding purity-release thresholds and cold-chain packaging. These inconsistencies limit a higher Documentation Quality score until the supplier’s public policies are fully reconciled.
02 / TESTING EVIDENCE
Baltic Peptides maintains a public COA framework and states that each production batch is submitted to an independent accredited laboratory before release. Its current COA page identifies Janoshik Analytical as a primary testing partner and describes reverse-phase HPLC or LC-MS analysis, with batch-specific certificates published before dispatch.
Public COA Archive — Present · Batch-Specific Reports — Present · Janoshik Identified — Yes · HPLC Purity — Present / Supplier-Published · LC-MS Identity — Present on applicable compounds · Lot Code — Present · Test Date — Present · External Lab Verification — Available on linked reports
PSR NOTE
Baltic Peptides provides strong testing transparency through public batch-level documentation, named external laboratory use, and clear descriptions of HPLC/LC-MS methods. However, PSR identified conflicting purity-release thresholds across current supplier pages, so testing quality and documentation consistency are scored separately.
SUPPLIER-STATED
Claims made by Baltic Peptides regarding catalog-wide testing frequency, batch-release standards, external-laboratory coverage, and historical traceability that PSR has not independently validated across every active lot.
DOCUMENT OBSERVED
Information directly displayed in Baltic Peptides’ public COA archive, product pages, FAQ, shipping pages, and linked third-party testing references.
PSR CONCLUSION
Baltic demonstrates strong batch-level testing transparency, but PSR is withholding an elite testing score until current purity-threshold language and broader certificate consistency are fully reconciled.
03 / SAMPLE COA OBSERVATIONS
DOCUMENT OBSERVED — SUPPLIER-HOSTED REPORT IMAGE; reviewed October 4, 2026.
Retatrutide 10 mg
Janoshik-branded task #225102 · Client: Baltic Peptides · Batch: BP-RETA10-001 · Testing ordered: August 19, 2026 · Sample received: August 24, 2026 · Analysis conducted: August 26, 2026 · Tests requested: Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide) · Displayed results: Retatrutide 11.82 mg; purity 99.485% · Direct laboratory verification: pending.
DOCUMENT OBSERVED — SUPPLIER-HOSTED REPORT IMAGE; reviewed October 4, 2026.
MOTS-c 40 mg
Janoshik-branded task #231871 · Client: Baltic Peptides · Batch: BP-MOTS40-001 · Testing ordered: September 7, 2026 · Sample received: September 14, 2026 · Analysis conducted: September 17, 2026 · Tests requested: MOTS-c analysis · Displayed results: MOTS-C 46.59 mg; purity 99.353% · Direct laboratory verification: pending.
PSR inspected user-supplied screenshots of report images displayed in Baltic Peptides’ public COA archive on October 4, 2026. The displayed sample names and batch identifiers match the archive entries for these two records. These numerical results are transcribed from supplier-hosted report images; PSR could not independently retrieve the corresponding laboratory verification pages. Report authenticity, analytical methods beyond the test labels shown, chain of custody, and applicability to currently shipped inventory remain unverified. Results concern the represented samples only and do not establish sterility, endotoxin status, safety, or suitability for human or animal use.
04 / LOT TRACEABILITY
Lot Traceability
Baltic Peptides provides strong batch-level traceability through unique lot codes, batch-specific COAs, and packing-slip references that correspond directly to published certificates. The supplier states that each production run receives its own lot code and that the batch reference on an order matches the certificate associated with that specific production run.
Positive Indicators
• Unique lot code assigned to each production run
• Batch-specific COA for each production lot
• Batch code printed on vial labeling
• Packing slip references the specific batch
• Public COA archive organized by compound and batch
• COAs published before or while the batch is on sale
• Product identity tied to batch documentation
• Laboratory report tied to the batch
• Historical batch documentation stated as archived
• COA requests supported for specific batch codes
Limitation
PSR has not independently verified the complete chain of custody from upstream production through laboratory submission, warehousing, and final fulfillment. Baltic’s lot-code and packing-slip system provides strong documentation traceability, but supplier claims of traceability from synthesis through final release remain only partially independently substantiated.
05 / PRICING VISIBILITY
Pricing Visibility
Baltic Peptides provides strong public pricing visibility. Product pages display listed prices, available strengths, quantity-based discounts, stock status, and shipping information without requiring an account, making direct supplier comparison relatively straightforward.
PSR Observation — Baltic Peptides provides excellent pricing transparency. Researchers can review current prices, size options, volume discounts, stock status, and shipping information before checkout without creating an account. This supports a high Pricing Transparency score.
06 / COMPANY & SUPPLIER TRANSPARENCY
Supplier Name — Baltic Peptides · Fulfillment Location Listed — Lithuania, European Union · Public Contact Page — Available · Public Support Email — Available · Shipping Policy — Available · FAQ — Available · Research-Use Disclaimer — Available · Public COA Archive — Available · Public Legal-Entity Name — Not Clearly Established by PSR · Public Registration Number — Not Clearly Established by PSR
Baltic Peptides provides substantial customer-facing transparency through public contact information, Lithuania-based fulfillment disclosures, shipping documentation, research-use policies, public pricing, and a batch-specific COA system. However, PSR has not yet established the same level of public corporate-identification detail seen at the highest-scoring suppliers, including a clearly verified legal-entity name, registration number, and corporate address.
ITEMS REQUIRING CONTEXT
Public legal-entity identification · Company-registration details · Relationship between Baltic Peptides and any upstream production partners · Lithuania fulfillment vs. legal headquarters · Conflicting 98% vs. 99% purity-release language · Cold-chain/thermal-protection policy consistency · Conflicting public affiliate terms
07 / EVIDENCE CLASSIFICATION
VERIFIED IN PUBLIC DOCUMENTATION — PSR directly observed Baltic Peptides’ public COA archive, batch-specific certificate structure, Lithuania-based fulfillment disclosures, batch-traceable packing-slip claims, public pricing, contact information, shipping policies, research-use restrictions, and current statements identifying Janoshik as an external laboratory used for HPLC-UV or LC-MS analysis. SUPPLIER-STATED — Baltic Peptides states that every production batch is independently tested, each order can be traced to the same batch shown on its COA, and thermal protection is standard on every shipment. NOT DETERMINED — PSR has not independently established complete chain of custody, verified every active lot’s laboratory report, confirmed the supplier’s full legal-entity and registration details, or reconciled conflicting public language regarding the 98% versus 99% purity-release threshold and differing affiliate-program terms.
08 / BALANCED ASSESSMENT
DOCUMENTATION STRENGTHS
Public COA archive · Batch-specific certificates · Unique lot codes · Public pricing · Product strengths and stock status · Lithuania fulfillment disclosure · Janoshik identified as an external testing laboratory · HPLC-UV / LC-MS methods publicly described · Batch references tied to order documentation · Public shipping and research-use policies
AREAS FOR FURTHER REVIEW
Clarification of 98% vs. 99% purity-release language · Direct review of more current underlying laboratory reports · Full legal-entity and registration verification · Complete chain-of-custody verification · Cold-chain / thermal-protection policy consistency · Conflicting public affiliate terms · Long-term historical COA accessibility
PSR ASSESSMENT
Preliminary PSR Transparency Score: 89 / 100 — Strong Transparency
Baltic Peptides presents a strong public transparency framework, particularly through its batch-specific COA system, lot-level traceability, public pricing, Lithuania-based fulfillment disclosures, and identification of external analytical testing. These features support a Strong preliminary PSR transparency rating.
The main limitations are documentation consistency and corporate-identification depth. PSR identified conflicting public language regarding the applicable purity-release threshold and shipping-protection practices, and has not yet independently established the supplier’s full legal-entity and registration details. PSR therefore gives Baltic substantial credit for evidence accessibility while reserving a higher score until these issues are reconciled.
Visit Baltic Peptides Website →
SAVE 10% — Use code peptidesupplyreport10
09 / SOURCES REVIEWED
Baltic Peptides official website - Baltic Peptides public COA archive - Baltic Peptides product pages - Baltic Peptides FAQ - Baltic Peptides shipping information - Baltic Peptides contact/support pages - Baltic Peptides affiliate-program pages - Public references to Janoshik Analytical testing
Retatrutide 10 mg — Laboratory verification link — direct verification pending
MOTS-c 40 mg — Laboratory verification link — direct verification pending
DISCLAIMER
PSR evaluates supplier transparency and publicly available documentation for informational and research purposes. A PSR score is not a certification, laboratory guarantee, medical recommendation, safety determination, regulatory approval, or guarantee of product identity, purity, efficacy, legality, or suitability for human or animal use. Supplier-stated testing and traceability claims remain classified according to the evidence directly available to PSR at the time of review, and individual laboratory results apply only to the specific submitted samples represented by those reports.